Diabetes Drug Protects Heart During Cancer Treatment
- A new study reveals that a commonly prescribed diabetes medication could substantially improve long-term recovery for cancer patients by decreasing their risk of heart failure.
- Cancer treatments, especially chemotherapy, can lead to severe cardiovascular complications, impacting a patient's health and quality of life.
- Researchers at UEA’s norwich Medical School have found that SGLT2 inhibitors, a type of diabetes medication, can substantially protect the heart during and after cancer therapy.
Diabetes Drug Shows Promise in Protecting Hearts of Cancer Patients
Table of Contents
Published:
A new study reveals that a commonly prescribed diabetes medication could substantially improve long-term recovery for cancer patients by decreasing their risk of heart failure. The research comes from the University of East Anglia (UEA).
Protecting the Heart During Cancer Treatment
Cancer treatments, especially chemotherapy, can lead to severe cardiovascular complications, impacting a patient’s health and quality of life. It’s reported that “up to 20 percent of cancer patients who have had chemotherapy go on to develop heart problems,with up to 10 percent having heart failure.”
Researchers at UEA’s norwich Medical School have found that SGLT2 inhibitors, a type of diabetes medication, can substantially protect the heart during and after cancer therapy. The systematic review and meta-analysis, featured in the European Journal of Preventive Cardiology, included 13 studies with 88,273 cancer patients and survivors.
the analysis showed that using SGLT2 inhibitors reduced hospital admissions for heart failure by over 50 percent.The benefits were especially noticeable among breast cancer patients receiving anthracycline chemotherapy. In this group, new heart failure cases dropped by an remarkable 71 percent.
A Promising Breakthrough in Cardiotoxicity
This study marks the first presentation of a medication effectively reducing heart failure incidents and hospitalizations in cancer patients and survivors.
Chemotherapy has significantly improved patient outcomes, but it also presents risks. As noted, “Cancer is currently one of the leading causes of premature death worldwide,” and while “chemotherapy has played an instrumental role in improving patient outcomes,” it can lead to cardiac issues.
SGLT2 inhibitors are known for their cardiovascular benefits. They can alleviate heart failure symptoms like breathlessness and tiredness and reduce frailty risk. The key question was whether these inhibitors could protect the heart during and after cancer treatment.
chemotherapy is vital for cancer treatment but can unintentionally harm the cardiovascular system. Anthracyclines, in particular, can damage the heart muscle, increasing the risk of heart failure, reducing quality of life, and raising hospitalization rates.
Future Implications for Cancer Care
While the results are encouraging, further research is needed to confirm these benefits.There is optimism about the potential role of SGLT2 inhibitors in future cancer care.
We hope that this type of medication could in future be used as routine for cancer patients.
The study involved collaboration with medical centers across europe, including hospitals in Dundee, Italy, and Spain. With further validation, this finding could significantly advance supportive care for cancer patients worldwide.
the complete study is available in the european Journal of Preventive Cardiology.
Diabetes Drug Shows Promise in Protecting Hearts of Cancer Patients: Your Questions Answered
A recent study from teh university of east Anglia (UEA) has shed light on how a common diabetes medication could considerably benefit cancer patients by reducing their risk of heart failure. Here’s a breakdown of what you need to know.
What are SGLT2 inhibitors and how do they protect the heart during cancer treatment?
SGLT2 (Sodium-glucose cotransporter-2) inhibitors are a class of drugs primarily used to treat type 2 diabetes.They work by preventing the kidneys from reabsorbing glucose, leading to lower blood sugar levels. Recent research indicates that these drugs also offer critically important cardiovascular benefits, particularly in protecting the heart during and after cancer treatments like chemotherapy.
how does chemotherapy affect the heart?
Chemotherapy, while effective in treating cancer, can have detrimental side effects on the heart. Specifically:
Cardiotoxicity: Chemotherapy drugs, such as anthracyclines (e.g., doxorubicin), can damage the heart muscle.
Increased Risk of Heart Failure: This damage can lead to heart failure, reducing the patient’s quality of life and increasing hospitalization rates.
Prevalence of Heart Issues: Studies suggest that up to 20% of cancer patients who undergo chemotherapy develop heart problems, with up to 10% experiencing heart failure.
What did the UEA study reveal about SGLT2 inhibitors and cancer patients?
The study conducted by researchers at UEA’s Norwich Medical School, featured in the European Journal of Preventive